GSK at FoG London 2027
Jan 27–28, 2027 London, UK ~8.3k attendees Website
GSK takes part in 5 sessions at FoG London 2027 in London, its home city. Its program centres on data and AI in drug discovery, from biobank and multi-omic data to protein AI models. It also weighs whether AI is producing real breakthroughs or just faster trial and error, and where data science fits in oncology discovery and translation.
| Organization | FoG London 2027 Attendance |
|---|---|
GSK London, UK | |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, oncology and immunology. | Talk Wed Jan 27 14:30–15:00 Making Biobank Data Useful for Drug Discovery How genetic data from large biobanks can point to promising drug targets and strengthen the evidence behind clinical development. Talk Wed Jan 27 14:30–15:00 Protein AI Models for Drug Discovery How AI models trained on protein sequences and structures could help explain disease and find drug targets. Talk Wed Jan 27 16:30–17:00 Data Science Opportunities in Oncology Discovery & Translation How combining genomic data, gene-disruption experiments and real-world patient records can link cancer drug targets to mechanisms and patient groups. Panel Wed Jan 27 17:30–18:00 Using High Dimensional Multi-Omic Data in Drug Discovery & Translational Research How combining several layers of molecular data can reveal drug targets and biomarkers, and what slows their path to the clinic. Panel Thu Jan 28 11:30–12:00 Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error? Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured. |
Find decision makers at GSK
Tell us what you sell and we’ll find the people at GSK most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by Front Line Genomics or the Festival of Genomics. Submit a correction